Skip to content
Screener

Crinetics Pharmaceuticals CRNX Business Segments — Research And Development Stock Based Compensation

Similar metrics at other companies

Cytek Biosciences, Inc. logo
CTKBReportable Segment — Research and development (excluding stock-based compensation)
$8.65M+16.8%
Mirum Pharmaceuticals, Inc. logo
MIRMReportable Segment — Research and development expenses (excluding stock-based compensation)
$76.3M+98.5%
Spyre Therapeutics, Inc. logo
SYREReportable Segment — Research and development, excluding compensation and share-based compensation
$46.89M+39.8%
Shattuck Labs, Inc. logo
STTKReportable Segment — Research and development equity compensation
$1.04M+50.8%
Biogen logo
BIIBReportable Segment — Research and development:
$167.1M-0.7%
Bicara Therapeutics logo
BCAXReportable Segment — Research and development personnel cost and other (including stock-based compensation)
$9.12M+79.0%

Other financials

Income statement

See full
Revenue$10.7M+2,873%
Gross profit$10.5M+2,818%
Operating income-$140.4M-26.0%
Net income-$127.8M-32.1%
EPS (diluted)-$1.23-18.3%

Balance sheet

See full
Cash & equivalents$115.1M+20.1%
Total debt$47.9M-5.8%
Total equity$1.3B+2.1%
Total assets$1.4B+2.9%

Cash flow

See full
Operating cash flow-$124.7M-41.0%
CapEx$820.0K-33.8%
Free cash flow-$125.5M-40.0%

Valuation

See full
Market cap$8.9B+233%
Enterprise value$8.84B+231%
P/S492.8×-1,427×

Profitability

See full
Gross margin150%-15.6pp
Operating margin-3,020.3%-1,463pp
Net margin-2,747.2%-1,328pp
FCF margin-2,321.7%-1,122pp

Returns & leverage

See full
Return on equity-39.2%+14.5pp
Debt / equity0×0.0×
Current ratio18.6×-3.9×

Where this comes from

Reported directly by Crinetics Pharmaceuticals in its filing.

Tagged under the XBRL concept crnx:ResearchAndDevelopmentStockBasedCompensation.

The source filing: Crinetics Pharmaceuticals’s 10-Q, filed May 7, 2026.

Filed
May 7, 2026, 4:21 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001658247-26-000040
Line itemThree months ended March 31, 2026Three months ended March 31, 2025
Atumelnant(20,267)(7,749)
Other research and development programs(9,667)(7,058)
Research and development personnel expenses(30,649)(25,627)
Research and development stock-based compensation(19,328)(11,819)
Other research and development (1)(8,301)(6,736)
Total research and development expenses(100,081)(76,240)
Selling, general and administrative
Other selling, general and administrative expenses (2)(20,442)(14,774)

Item 1. Condensed Consolidated Financial Statements (Unaudited)

FAQ

What is Crinetics Pharmaceuticals's business segments — research and development stock based compensation?
Crinetics Pharmaceuticals (CRNX) reported business segments — research and development stock based compensation of $19.33M in Q1 2026.
How has Crinetics Pharmaceuticals's business segments — research and development stock based compensation changed year-over-year?
Crinetics Pharmaceuticals's business segments — research and development stock based compensation increased by 63.5% year-over-year, from $11.82M to $19.33M.
What does business segments — research and development stock based compensation mean?
This metric quantifies the non-cash expense related to stock-based awards granted to research and development personnel. It reflects the company's strategy for incentivizing and retaining scientific talent through equity participation. This is a key component of total R&D investment and impacts the company's overall operating expenses.

Ask your AI about Crinetics Pharmaceuticals's business segments — research and development stock based compensation.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude